Add BrightSurf on Google Email

Dual treatments help PTSD and depression

A sequential approach to treating comorbid PTSD and major depressive disorder has shown promising results in a randomized control trial. The study found that combining Cognitive Processing Therapy (CPT) and Behavioral Activation Therapy (BA) led to meaningful reductions in PTSD and depression severity.

SourceFlinders University·JournalJournal of Anxiety Disorders·DateFeb 4, 2021

Study links brain cells to depression

A new study found a reduced number of astrocytes in the brains of depressed adults compared to non-depressed individuals. The study suggests that targeting these cells may lead to improved treatment options for depression.

SourceFrontiers·JournalFrontiers in Psychiatry·DateFeb 4, 2021

Antibiotic may improve outcomes for depression in people with low level inflammation

A recent study found that minocycline, an antibiotic with anti-inflammatory properties, significantly improved depressive symptoms in patients with treatment-resistant depression and low-grade peripheral inflammation. The trial showed that patients with higher C-reactive protein levels responded better to minocycline treatment.

SourceNIHR Maudsley Biomedical Research Centre·JournalNeuropsychopharmacology·DateJan 27, 2021

Common workplace interactions can trigger suicidal thoughts for employees with mood disorders

A study by Kayla Follmer and Jake Follmer found that low-grade forms of workplace mistreatment can amplify suicidal thoughts in employees with depression or bipolar disorder. The researchers surveyed 279 American adults and discovered that perceived mistreatment, job engagement, and suicidal ideation are linked.

SourceWest Virginia University·JournalOrganizational Behavior and Human Decision Processes·DateJan 14, 2021

Repeated ketamine infusions reduce PTSD symptom severity

A study conducted by researchers from the Icahn School of Medicine at Mount Sinai found that repeated ketamine infusions significantly reduced symptom severity in individuals with chronic PTSD. The improvement was rapid and maintained for several weeks afterwards, suggesting this may be a promising treatment option for PTSD patients.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalAmerican Journal of Psychiatry·DateJan 5, 2021

'Alarming' COVID-19 study shows 80% of respondents report significant symptoms of depression

A national survey of over 1,000 young US adults finds alarming levels of loneliness associated with significant mental health issues, including depression, anxiety, substance use, and addiction. The study emphasizes the importance of providing access to psychological help and promoting social connectedness to address these problems.

SourceTaylor & Francis Group·JournalJournal of Psychoactive Drugs·DateNov 16, 2020

Tackling teenage depression: Albert Einstein College of Medicine and Montefiore Health System receive $4 million NIH grant to support search for biomarkers for severe depression

Researchers at Albert Einstein College of Medicine and Montefiore Health System are searching for biomarkers to predict the duration and severity of depression in adolescents. The goal is to identify teens who need more significant help with their depression, potentially leading to new treatments.

Single brain region links depression and anxiety, heart disease, and treatment sensitivity

A new study suggests that targeting a single brain region called the subgenual anterior cingulate cortex (sgACC) could lead to better outcomes for people with depression and anxiety. Over-activity in sgACC underlies several key symptoms of mood and anxiety disorders, but an antidepressant only successfully treats some of the symptoms.

SourceUniversity of Cambridge·JournalNature Communications·DateOct 26, 2020

A putative mechanism that switches brain pathology from anxiety to depression discovered

Researchers discovered a novel brain mechanism that links anxiety and depression, showing unique cellular mechanisms activate as one pathology progresses into another. The 'switch' involves astrocytes and cytoskeletal mechanisms, which may be targeted for new classes of psychotropic drugs.

SourceSt. Petersburg State University·JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry·DateOct 2, 2020